Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

McGill University

$135,000.00

Individualized prognosis and prediction of cognitive decline in individuals with subjective cognitive decline

FY 2020-21

Summary
Worldwide, Alzheimer's disease (AD) is one of the largest health care costs. In Canada, approximately one million cases of AD are expected by 2030, costing the health care system over $20 billion annually. AD can be present in the brain more than a decade before clinical symptoms start, making it impossible to treat the important early damage caused by the disease. In addition to these pre-clinical brain changes, subtle cognitive changes detectable by the individual may also occur years before meeting the criteria for mild cognitive impairment (MCI) or AD. However, accurately identifying people at risk of AD before symptoms appear is extremely difficult. Nevertheless, this pre-clinical period is the earliest phase of progressive AD where disease-modifying treatments are likely to be most effective. To identify individuals at risk of AD, we propose to study those with subjective cognitive decline (SCD). These are individuals with perceived cognitive deficits but they do not show objective cognitive decline on standardized tests. Individuals who report SCD have a 3-5x increased risk of progressing to dementia and therefore make ideal candidates for prevention strategies with lifestyle changes or as subjects in clinical trials. The goal of the current project is to develop and validate a tool that combines MRI, clinical risk factors, and cognitive testing to be used in clinical settings to determine 1) which patients will develop cognitive decline, 2) determine their rate of decline, and 3) determine who will progress to MCI. This prognostic tool will help clinicians develop individualized prevention/treatment strategies. This method will also help optimize clinical trials by including people who are likely to progress to AD. Overall, this research will make clinical trials more powerful, allowing new drugs to be properly tested with fewer participants over shorter durations, bringing new treatments to patients sooner.
Program
CIHR Fellowship
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
440609
Name
Morrison Cassandra
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Individualized prognosis and prediction of cognitive decline in individuals with subjective cognitive decline
Programtype2
Fellowship Programs
Orgnameinp2
McGill University
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Aging; Alzheimer'S Disease; Biomarkers; Cognitive Decline; Cognitive Testing; Dementia; Image Processing; Magnetic Resonance Imaging; Prognosis; Subjective Cognitive Decline
Abstract
Worldwide, Alzheimer's disease (AD) is one of the largest health care costs. In Canada, approximately one million cases of AD are expected by 2030, costing the health care system over $20 billion annually. AD can be present in the brain more than a decade before clinical symptoms start, making it impossible to treat the important early damage caused by the disease. In addition to these pre-clinical brain changes, subtle cognitive changes detectable by the individual may also occur years before meeting the criteria for mild cognitive impairment (MCI) or AD. However, accurately identifying people at risk of AD before symptoms appear is extremely difficult. Nevertheless, this pre-clinical period is the earliest phase of progressive AD where disease-modifying treatments are likely to be most effective. To identify individuals at risk of AD, we propose to study those with subjective cognitive decline (SCD). These are individuals with perceived cognitive deficits but they do not show objective cognitive decline on standardized tests. Individuals who report SCD have a 3-5x increased risk of progressing to dementia and therefore make ideal candidates for prevention strategies with lifestyle changes or as subjects in clinical trials. The goal of the current project is to develop and validate a tool that combines MRI, clinical risk factors, and cognitive testing to be used in clinical settings to determine 1) which patients will develop cognitive decline, 2) determine their rate of decline, and 3) determine who will progress to MCI. This prognostic tool will help clinicians develop individualized prevention/treatment strategies. This method will also help optimize clinical trials by including people who are likely to progress to AD. Overall, this research will make clinical trials more powerful, allowing new drugs to be properly tested with fewer participants over shorter durations, bringing new treatments to patients sooner.
Competitiondate
202012
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Morrison, Cassandra
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~
McGill University - $135,000 Grant (2020-21) | Canada Spends